HM Payson & Co. reduced its stake in Becton Dickinson and Co (NYSE:BDX) by 0.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 75,093 shares of the medical instruments supplier’s stock after selling 216 shares during the period. HM Payson & Co.’s holdings in Becton Dickinson and were worth $20,423,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of BDX. Ilmarinen Mutual Pension Insurance Co bought a new stake in Becton Dickinson and in the third quarter worth $8,221,000. Colony Group LLC increased its stake in Becton Dickinson and by 0.7% during the third quarter. Colony Group LLC now owns 16,052 shares of the medical instruments supplier’s stock worth $4,060,000 after acquiring an additional 110 shares during the last quarter. Voya Investment Management LLC lifted its stake in shares of Becton Dickinson and by 29.6% in the 3rd quarter. Voya Investment Management LLC now owns 478,546 shares of the medical instruments supplier’s stock valued at $121,053,000 after purchasing an additional 109,227 shares during the last quarter. Redpoint Investment Management Pty Ltd lifted its stake in shares of Becton Dickinson and by 2.5% in the 3rd quarter. Redpoint Investment Management Pty Ltd now owns 17,726 shares of the medical instruments supplier’s stock valued at $4,484,000 after purchasing an additional 428 shares during the last quarter. Finally, Endurant Capital Management LP purchased a new position in shares of Becton Dickinson and in the 3rd quarter worth approximately $5,581,000. Institutional investors and hedge funds own 85.37% of the company’s stock.
Several research analysts have commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Becton Dickinson and from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. KeyCorp boosted their price objective on Becton Dickinson and from $284.00 to $298.00 and gave the company an “overweight” rating in a report on Wednesday, January 22nd. Piper Sandler lifted their target price on Becton Dickinson and from to and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Cowen lowered shares of Becton Dickinson and from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $306.00 to $275.00 in a research note on Thursday, February 6th. Finally, TheStreet lowered shares of Becton Dickinson and from a “b” rating to a “c+” rating in a research note on Monday, March 9th. Nine analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Becton Dickinson and has a consensus rating of “Hold” and an average target price of $278.00.
In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 19,675 shares of Becton Dickinson and stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $275.15, for a total transaction of $5,413,576.25. Following the completion of the sale, the chief executive officer now directly owns 227,647 shares in the company, valued at approximately $62,637,072.05. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Claire Fraser sold 1,500 shares of Becton Dickinson and stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $258.72, for a total transaction of $388,080.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 109,208 shares of company stock worth $30,137,672. 0.12% of the stock is owned by insiders.
Shares of NYSE BDX traded up $9.46 during trading hours on Thursday, hitting $213.06. 683,044 shares of the stock were exchanged, compared to its average volume of 3,003,789. Becton Dickinson and Co has a 12 month low of $197.75 and a 12 month high of $286.72. The firm has a fifty day moving average price of $243.40 and a 200-day moving average price of $256.52. The company has a quick ratio of 0.55, a current ratio of 0.96 and a debt-to-equity ratio of 0.80. The company has a market cap of $55.01 billion, a PE ratio of 78.33, a PEG ratio of 1.86 and a beta of 1.14.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $2.65 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.63 by $0.02. Becton Dickinson and had a net margin of 4.96% and a return on equity of 15.50%. The business had revenue of $4.23 billion for the quarter, compared to analyst estimates of $4.19 billion. During the same period in the previous year, the company earned $2.70 earnings per share. The business’s revenue for the quarter was up 1.6% on a year-over-year basis. As a group, equities analysts anticipate that Becton Dickinson and Co will post 11.9 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 1.48%. The ex-dividend date of this dividend is Monday, March 9th. Becton Dickinson and’s dividend payout ratio is presently 27.05%.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: What are the qualifications of a portfolio manager?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.